SubHero Banner

Imfinzi® (durvalumab) plus Imjudo® (tremelimumab-actl) – New indication

November 11, 2022 - AstraZeneca announced the FDA approval of Imfinzi (durvalumab), in combination with Imjudo (tremelimumab-actl) and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Download PDF